3XFLAG-VP64-SadCas9-NLS-VP64 Citations (2)

Originally described in: A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene.
Kemaladewi DU, Bassi PS, Erwood S, Al-Basha D, Gawlik KI, Lindsay K, Hyatt E, Kember R, Place KM, Marks RM, Durbeej M, Prescott SA, Ivakine EA, Cohn RD Nature. 2019 Aug;572(7767):125-130. doi: 10.1038/s41586-019-1430-x. Epub 2019 Jul 24. PubMed Journal

---

Articles Citing 3XFLAG-VP64-SadCas9-NLS-VP64

Articles
CRISPRa-induced upregulation of human LAMA1 compensates for LAMA2-deficiency in Merosin-deficient congenital muscular dystrophy. Arockiaraj AI, Johnson MA, Munir A, Ekambaram P, Lucas PC, McAllister-Lucas LM, Kemaladewi DU. bioRxiv [Preprint]. 2023 Mar 7:2023.03.06.531347. doi: 10.1101/2023.03.06.531347. PubMed
Tunable, proteolytic dosage control of CRISPR-Cas systems enables precise gene therapy for dosage sensitive disorders. Katz N, An C, Lee YJ, Tycko J, Zhang M, Kang J, Bintu L, Bassik MC, Huang WH, Gao XJ. bioRxiv [Preprint]. 2025 Sep 19:2024.10.09.617463. doi: 10.1101/2024.10.09.617463. PubMed

If you have published an article using this material, please email us at to have your article added to this page.